PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21596473-8	2011	When the ATII-like cells were exposed to either bleomycin or a TGF(b1)-EGF cocktail, they underwent phenotypic changes including acquisition of a mesenchymal/fibroblastic morphology, upregulation of mesenchymal markers (Col1, Vim, a-Sma, and S100A4), and downregulation of surfactant proteins and E-cadherin.	Bleomycin	48-57	immunoglobulin mu binding protein 2	Mus musculus	233-236	
29940932-10	2018	When endothelial cells were treated with TGF-beta, alpha-smooth muscle actin (SMA) expression and collagen production were increased only in those cells from bleomycin-treated mouse lungs.	Bleomycin	158-167	immunoglobulin mu binding protein 2	Mus musculus	51-76	
29940932-10	2018	When endothelial cells were treated with TGF-beta, alpha-smooth muscle actin (SMA) expression and collagen production were increased only in those cells from bleomycin-treated mouse lungs.	Bleomycin	158-167	immunoglobulin mu binding protein 2	Mus musculus	78-81	
25844688-9	2015	On day 21, combination therapy ameliorated bleomycin-induced increase of fibrosis score, collagen deposition, protein and gene expression of SMA, mRNA levels of collagens-I and -III, matrix metalloproteinase-9 and -2 activities more than monotherapy.	Bleomycin	43-52	immunoglobulin mu binding protein 2	Mus musculus	141-144